Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial (Q38375842)
Jump to navigation
Jump to search
scientific article published on March 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial |
scientific article published on March 2010 |
Statements
1 reference
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial (English)
1 reference
Andrew R Zolopa
1 reference
Daniel S Berger
1 reference
Harry Lampiris
1 reference
Lijie Zhong
1 reference
Steven L Chuck
1 reference
Jeffrey V Enejosa
1 reference
Brian P Kearney
1 reference
Andrew K Cheng
1 reference
1 March 2010
1 reference
1 reference
Identifiers
1 reference